147 related articles for article (PubMed ID: 29515397)
1. A Case of Lung Adenocarcinoma with Marked Improvement of Pulmonary Lymphangitic Carcinomatosis by Adding Bevacizumab to Cisplatin and Pemetrexed.
Natsume M; Honda T; Haruyama T; Ishihara M; Fukasawa Y; Sakamoto T; Tanzawa S; Usui R; Ota S; Ichikawa Y; Watanabe K; Seki N
Case Rep Oncol; 2017; 10(3):1065-1069. PubMed ID: 29515397
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
4. Complete Metabolic Response in Adenocarcinoma Lung With Lymphangitic Carcinomatosis.
Goyal H; Kishore S; Ganesan P; Halanaik D
Clin Nucl Med; 2023 Mar; 48(3):e133-e134. PubMed ID: 36252925
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
Fukushima T; Wakatsuki Y; Kobayashi T; Sonehara K; Tateishi K; Yamamoto M; Masubuchi T; Yoshiike F; Hirai K; Hachiya T; Koizumi T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1043-1050. PubMed ID: 29644460
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer.
Im Y; Lee H; Lee HY; Baek SY; Jeong BH; Lee K; Kim H; Kwon OJ; Han J; Lee KS; Ahn MJ; Kim J; Um SW
Transl Lung Cancer Res; 2021 Nov; 10(11):4130-4140. PubMed ID: 35004244
[TBL] [Abstract][Full Text] [Related]
7. Two cases of lymphangitic carcinomatosis as the primary symptom of colorectal carcinoma that achieved complete remission using combination anti-EGFR antibody therapy.
Toshima H; Ikusue T; Hisamatsu A; Kobayashi K; Shimada K
Onco Targets Ther; 2019; 12():2089-2093. PubMed ID: 30936723
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary lymphangitic carcinomatosis: chronicity of radiographic findings in long-term survivors.
Ikezoe J; Godwin JD; Hunt KJ; Marglin SI
AJR Am J Roentgenol; 1995 Jul; 165(1):49-52. PubMed ID: 7785630
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary Lymphangitic Carcinomatosis due to Renal Cell Carcinoma.
Guddati AK; Marak CP
Case Rep Oncol; 2012 May; 5(2):246-52. PubMed ID: 22679431
[TBL] [Abstract][Full Text] [Related]
10. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
Barlesi F; Scherpereel A; Gorbunova V; Gervais R; Vikström A; Chouaid C; Chella A; Kim JH; Ahn MJ; Reck M; Pazzola A; Kim HT; Aerts JG; Morando C; Loundou A; Groen HJ; Rittmeyer A
Ann Oncol; 2014 May; 25(5):1044-52. PubMed ID: 24585722
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT in assessment of pulmonary lymphangitic carcinomatosis.
Prakash P; Kalra MK; Sharma A; Shepard JA; Digumarthy SR
AJR Am J Roentgenol; 2010 Jan; 194(1):231-6. PubMed ID: 20028927
[TBL] [Abstract][Full Text] [Related]
12. Lymphangitic carcinomatosis as the initial manifestation of primary signet-ring cell adenocarcinoma of the lung: A case report.
Corredor-Orlandelli D; Vargas L
Rare Tumors; 2023; 15():20363613231164017. PubMed ID: 36937819
[TBL] [Abstract][Full Text] [Related]
13. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.
Argiris A; Bauman JE; Ohr J; Gooding WE; Heron DE; Duvvuri U; Kubicek GJ; Posluszny DM; Vassilakopoulou M; Kim S; Grandis JR; Johnson JT; Gibson MK; Clump DA; Flaherty JT; Chiosea SI; Branstetter B; Ferris RL
Ann Oncol; 2016 Aug; 27(8):1594-600. PubMed ID: 27177865
[TBL] [Abstract][Full Text] [Related]
14. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
Michelsen L; Sørensen JB
Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary lymphangitic carcinomatosis from recurrent gastric cancer 19 years after primary resection: a case report.
Shioya S; Masuda T; Iwamoto H; Yamaguchi K; Sakamoto S; Horimasu Y; Miyamoto S; Nakashima T; Fujitaka K; Hamada H; Hattori N
Clin J Gastroenterol; 2021 Apr; 14(2):484-488. PubMed ID: 33453005
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
[TBL] [Abstract][Full Text] [Related]
17. Metastatic colorectal micropapillary carcinoma presenting as lymphangitic lung carcinomatosis.
Lopez-Garcia CA; Garcia-Hernandez I; López-Sotomayor DM; Martínez-Amador C; Rodríguez-Prado A; Esteban-Zubero E; Alatorre-Jimenez MA; Dono A; Pérez-Saucedo JE
Clin J Gastroenterol; 2021 Feb; 14(1):193-197. PubMed ID: 33040282
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma.
Zhou CZ; Qin YY; Xie ZH; Zhang JX; Ou-Yang M; Li SY; Chen RC
Chin J Cancer Res; 2014 Dec; 26(6):705-10. PubMed ID: 25561769
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
Tsutani Y; Miyata Y; Masuda T; Fujitaka K; Doi M; Awaya Y; Kuyama S; Kitaguchi S; Ueda K; Hattori N; Okada M
BMC Cancer; 2018 Dec; 18(1):1231. PubMed ID: 30526545
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
